Finance

Lists
Why is 950210 up 2,52%?
Dive Deeper
950210:KRX
Prestige Biopharma Ltd
₩5 690,00
+2,52%
(+140,00) 1D
16 Okt., 15:30:30 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 950210...
Open
₩5 370
High
₩5 770
Low
₩5 370
Mkt. cap
341,95 mjd
Avg. vol.
33,56 k
Volume
33,97 k
52-wk high
₩14 120
52-wk low
₩4 945
EPS
-₩892
Shares outstanding
60,10 m
No. of employees
64
Open
₩5 370
High
₩5 770
Low
₩5 370
Mkt. cap
341,95 mjd
Avg. vol.
33,56 k
Volume
33,97 k
52-wk high
₩14 120
52-wk low
₩4 945
EPS
-₩892
Shares outstanding
60,10 m
No. of employees
64
News stories
From web sources and news partners
About Prestige Biopharma Ltd
CEO-
Employees64
Founded2015
Headquarters-
Sector-
Websiteprestigebiopharma.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,36 mjd
7,81 mjd
509,20 m
15,39 mjd
Cost of goods sold
2,23 mjd
10,17 mjd
12,23 mjd
17,68 mjd
Cost of revenue
2,23 mjd
10,17 mjd
12,23 mjd
17,68 mjd
Research and development expenses
-
-
-
42,51 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
24,95 mjd
16,79 mjd
14,63 mjd
-36,73 mjd
Operating expense
24,95 mjd
16,79 mjd
14,63 mjd
20,81 mjd
Total operating expenses
27,18 mjd
26,96 mjd
26,86 mjd
38,49 mjd
Operating income
-24,82 mjd
-19,15 mjd
-26,35 mjd
-23,10 mjd
Other non operating income
4,06 mjd
-1,38 mjd
-3,05 mjd
7,24 mjd
EBT including unusual items
-20,76 mjd
-20,53 mjd
-29,40 mjd
-52,36 mjd
EBT excluding unusual items
-20,76 mjd
-20,53 mjd
-29,40 mjd
-23,56 mjd
Income tax expense
-69,96 m
-17,84 m
-20,29 m
-43,51 m
Effective tax rate
0,34%
0,09%
0,07%
0,08%
Other operating expenses
-
-
-
573,69 m
Net income
-12,62 mjd
-15,37 mjd
-20,56 mjd
-42,95 mjd
Net profit margin
-534,55%
-196,66%
-4 037,83%
-279,14%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
3,62 mjd
Interest expense
-
-
-
-6,92 mjd
Net interest expenses
-
-
-
-3,31 mjd
Depreciation and amortization charges
-
-
-
6,52 mjd
EBITDA
-19,37 mjd
-13,70 mjd
-20,90 mjd
-14,91 mjd
Gain or loss from assets sale
-
-
-
-6,37 m
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme